March 8, 2018
GSK, Innoviva get EC’s label update, once daily Relvar Ellipta as good as as twice-daily ICS/LABA for patients with asthma
The European Commission has approved a label update for the use of GlaxoSmithKline and Innoviva’s Relvar Ellipta, an inhaled corticosteroid (ICS) / long-acting β2-agonist (LABA)…